文献速递药物不良反应与药物警戒

28种抗抑郁药停药综合征:基于WHO数据库31,688例报告的药物警戒分析

Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database.
PubMed 文献 · Drug Saf · 2022-11-18

本研究基于VigiBase对28种抗抑郁药相关停药综合征报告进行病例/非病例不成比例分析,发现23种抗抑郁药报告显著不成比例,整体ROR为14.26,帕罗西汀、度洛西汀、文拉法辛和去甲文拉法辛临床优先级最高,男性、青少年、多药联用及较长治疗疗程者严重反应报告更多。

要点

  • 抗抑郁药整体停药综合征报告ROR为14.26,显著高于其他药物。
  • 帕罗西汀、度洛西汀、文拉法辛和去甲文拉法辛不成比例报告最强。
  • 男性、青少年、多药联用及长疗程者严重停药反应报告更多。

核心结论

  • 抗抑郁药与其他药物类别相比与停药综合征报告增加相关。
  • 临床医生应知晓不同抗抑郁药停药综合征倾向存在差异,特定患者特征者可能经历更严重症状。

研究设计与样本

  • 基于VigiBase的病例/非病例药物警戒研究,采用不成比例分析计算报告比值比(ROR)和贝叶斯信息成分(IC)。
  • 共纳入31,688例抗抑郁药相关停药综合征报告。

主要发现

  • 23种抗抑郁药检测到不成比例报告。
  • 抗抑郁药整体相较其他药物的ROR为14.26(95%CI 14.08-14.45),其他抗抑郁药为17.01(95%CI 16.73-17.29),SSRIs为13.65(95%CI 13.41-13.90),三环类为2.8(95%CI 2.59-3.02)。
  • 基于临床优先级排序,帕罗西汀、度洛西汀、文拉法辛和去甲文拉法辛不成比例报告最强,与丁丙诺啡相当。
  • 停药综合征报告为严重的情况更常见于男性、青少年、多药联用者及抗抑郁药治疗疗程较长者(p < 0.05)。

临床怎么用

  • 处方和停用抗抑郁药时,应关注具体药物停药综合征倾向的差异。
  • 对男性、青少年、多药联用及长疗程患者,应警惕更严重停药症状的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Evidence is lacking on withdrawal syndrome related to individual antidepressants and relevant risk factors for severe reactions. OBJECTIVE: To ascertain whether antidepressants are associated with an increased reporting of withdrawal syndrome as compared with other medications, and to investigate risk factors for severe reactions. METHODS: This is a case/non-case pharmacovigilance study, based on the VigiBase®, the WHO global database of individual case safety reports of suspected adverse drug reactions. We performed a disproportionality analysis of reports of antidepressant-related withdrawal syndrome (calculating reporting odds ratio [ROR] and Bayesian information component [IC]). We compared antidepressants to all other drugs, to buprenorphine (positive control), and to each other within each class of antidepressants (selective serotonin reuptake inhibitors [SSRIs], tricyclics and other antidepressants). Antidepressants with significant disproportionate reporting were ranked in terms of clinical priority. Serious versus non-serious reactions were compared. RESULTS: There were 31,688 reports of antidepressant-related withdrawal syndrome were found. A disproportionate reporting was detected for 23 antidepressants. The estimated ROR for antidepressants altogether, compared to all other drugs, was 14.26 (95% CI 14.08-14.45), 17.01 for other antidepressants (95% CI 16.73-17.29), 13.65 for SSRIs (95% CI 13.41-13.90) and 2.8 for tricyclics (95% CI 2.59-3.02). Based on clinical priority ranking, the strongest disproportionate reporting was found for paroxetine, duloxetine, venlafaxine and desvenlafaxine, being comparable to buprenorphine. Withdrawal syndrome was reported as severe more often in males, adolescents, persons in polypharmacy, and with a longer antidepressant treatment duration (p < 0.05). CONCLUSIONS: Antidepressants are associated with an increased reporting of withdrawal syndrome compared with other drug classes. When prescribing and discontinuing antidepressants, clinicians should be aware of the potentially different proclivity of withdrawal syndrome across individual antidepressants, and the liability to experience more severe withdrawal symptoms in relation to specific patient characteristics.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Gastaldon C, Schoretsanitis G, Arzenton E, et al. Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database. Drug Saf. 2022. PMID: 36400895. doi:10.1007/s40264-022-01246-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。